Copyright
©The Author(s) 2022.
World J Clin Cases. Dec 16, 2022; 10(35): 13122-13128
Published online Dec 16, 2022. doi: 10.12998/wjcc.v10.i35.13122
Published online Dec 16, 2022. doi: 10.12998/wjcc.v10.i35.13122
Figure 1 Changes in hemoglobin, hematocrit and blood lipids before and after oral administration of Roxadustat.
A: Changes in hemoglobin and hematocrit (January 10, 2020); B: Changes in blood lipids (January 2020). HGB: Hemoglobin and HCT: Hematocrit; HDL-C: High-density lipoprotein cholesterol; LDL-C: Low-density lipoprotein cholesterol; TG: Triglyceride; TC: Total cholesterol.
Figure 2 Changes in Ferritin, Transferrinsaturation, and serum potassium levels before and after (January 2020) the oral administration of Roxadustat.
A: Changes in Ferritin; B: Changes in Transferrinsaturation; C: Changes in serum potassium levels. FER: Ferritin; TSAT: Transferrinsaturation.
Figure 3
Magnetic resonance imaging: Encephalatrophy (June 2022).
- Citation: Xu C, Luo DG, Liu ZY, Yang D, Wang DD, Xu YZ, Yang J, Fu B, Qi AR. Response to roxadustat in a patient undergoing long-term dialysis and allergic to erythropoiesis-stimulating agents: A case report . World J Clin Cases 2022; 10(35): 13122-13128
- URL: https://www.wjgnet.com/2307-8960/full/v10/i35/13122.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v10.i35.13122